S&P 500   3,746.59 (-0.97%)
DOW   29,921.53 (-1.16%)
QQQ   280.14 (-0.65%)
AAPL   145.61 (-0.54%)
MSFT   247.20 (-0.80%)
META   139.73 (+0.54%)
GOOGL   101.46 (+0.03%)
AMZN   120.27 (-0.56%)
TSLA   239.22 (-0.66%)
NVDA   131.64 (-0.34%)
NIO   14.87 (-7.29%)
BABA   84.53 (+0.17%)
AMD   68.22 (+0.41%)
T   15.39 (-3.39%)
MU   54.69 (-0.07%)
CGC   3.10 (+0.98%)
F   12.37 (-1.12%)
GE   65.94 (-2.22%)
DIS   100.12 (-0.67%)
AMC   7.23 (-1.36%)
PYPL   94.35 (+0.55%)
PFE   43.12 (-2.27%)
NFLX   240.95 (+1.78%)
S&P 500   3,746.59 (-0.97%)
DOW   29,921.53 (-1.16%)
QQQ   280.14 (-0.65%)
AAPL   145.61 (-0.54%)
MSFT   247.20 (-0.80%)
META   139.73 (+0.54%)
GOOGL   101.46 (+0.03%)
AMZN   120.27 (-0.56%)
TSLA   239.22 (-0.66%)
NVDA   131.64 (-0.34%)
NIO   14.87 (-7.29%)
BABA   84.53 (+0.17%)
AMD   68.22 (+0.41%)
T   15.39 (-3.39%)
MU   54.69 (-0.07%)
CGC   3.10 (+0.98%)
F   12.37 (-1.12%)
GE   65.94 (-2.22%)
DIS   100.12 (-0.67%)
AMC   7.23 (-1.36%)
PYPL   94.35 (+0.55%)
PFE   43.12 (-2.27%)
NFLX   240.95 (+1.78%)
S&P 500   3,746.59 (-0.97%)
DOW   29,921.53 (-1.16%)
QQQ   280.14 (-0.65%)
AAPL   145.61 (-0.54%)
MSFT   247.20 (-0.80%)
META   139.73 (+0.54%)
GOOGL   101.46 (+0.03%)
AMZN   120.27 (-0.56%)
TSLA   239.22 (-0.66%)
NVDA   131.64 (-0.34%)
NIO   14.87 (-7.29%)
BABA   84.53 (+0.17%)
AMD   68.22 (+0.41%)
T   15.39 (-3.39%)
MU   54.69 (-0.07%)
CGC   3.10 (+0.98%)
F   12.37 (-1.12%)
GE   65.94 (-2.22%)
DIS   100.12 (-0.67%)
AMC   7.23 (-1.36%)
PYPL   94.35 (+0.55%)
PFE   43.12 (-2.27%)
NFLX   240.95 (+1.78%)
S&P 500   3,746.59 (-0.97%)
DOW   29,921.53 (-1.16%)
QQQ   280.14 (-0.65%)
AAPL   145.61 (-0.54%)
MSFT   247.20 (-0.80%)
META   139.73 (+0.54%)
GOOGL   101.46 (+0.03%)
AMZN   120.27 (-0.56%)
TSLA   239.22 (-0.66%)
NVDA   131.64 (-0.34%)
NIO   14.87 (-7.29%)
BABA   84.53 (+0.17%)
AMD   68.22 (+0.41%)
T   15.39 (-3.39%)
MU   54.69 (-0.07%)
CGC   3.10 (+0.98%)
F   12.37 (-1.12%)
GE   65.94 (-2.22%)
DIS   100.12 (-0.67%)
AMC   7.23 (-1.36%)
PYPL   94.35 (+0.55%)
PFE   43.12 (-2.27%)
NFLX   240.95 (+1.78%)
NASDAQ:HRTX

Heron Therapeutics - HRTX Stock Forecast, Price & News

$4.51
+0.04 (+0.89%)
(As of 10/6/2022 03:02 PM ET)
Add
Compare
Today's Range
$4.43
$4.63
50-Day Range
$2.74
$5.37
52-Week Range
$2.19
$12.79
Volume
56,438 shs
Average Volume
4.13 million shs
Market Capitalization
$462.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.75

Heron Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
94.9% Upside
$8.75 Price Target
Short Interest
Bearish
31.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.77) to ($0.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

656th out of 1,072 stocks

Pharmaceutical Preparations Industry

308th out of 534 stocks

HRTX stock logo

About Heron Therapeutics (NASDAQ:HRTX) Stock

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HRTX Stock News Headlines

Heron Therapeutics Is Not Out Of The Woods Yet
Heron Awaits FDA Decision On HTX-019
3 Stocks Expecting Good News From the FDA
Heron Shares Jump After Equity Financing, Q2 Earnings
Earnings Outlook For Heron Therapeutics
Heron Therapeutics To Axe 34% Jobs
Heron Therapeutics Misses Q1 EPS by 15c
See More Headlines
Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HRTX Company Calendar

Last Earnings
8/09/2022
Today
10/06/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HRTX
Employees
302
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.75
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+94.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-220,680,000.00
Net Margins
-239.34%
Pretax Margin
-239.34%

Debt

Sales & Book Value

Annual Sales
$86.35 million
Book Value
$0.76 per share

Miscellaneous

Free Float
97,480,000
Market Cap
$462.86 million
Optionable
Optionable
Beta
1.05

Key Executives

  • Dr. Barry D. Quart Pharm.D. (Age 65)
    Chairman & CEO
    Comp: $1.1M
  • Mr. John W. Poyhonen (Age 62)
    Pres & Chief Commercial Officer
    Comp: $722.35k
  • Mr. David L. Szekeres (Age 48)
    Exec. VP & COO
    Comp: $710.66k
  • Ms. Lisa Peraza (Age 45)
    VP & Chief Accounting Officer
    Comp: $474.1k
  • Ms. Kimberly J. ManhardMs. Kimberly J. Manhard (Age 62)
    Exec. VP of Drug Devel. & Director
    Comp: $739.8k
  • Mr. Sean T. Ristine (Age 52)
    Sr. VP of HR
  • Dr. Thomas B. Ottoboni Ph.D. (Age 63)
    Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational Sciences
  • Mr. Michael E. Mathews (Age 59)
    Sr. VP of Acute Care
  • Dr. Chris M. Storgard (Age 56)
    Chief Medical Officer













HRTX Stock - Frequently Asked Questions

Should I buy or sell Heron Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HRTX shares.
View HRTX analyst ratings
or view top-rated stocks.

What is Heron Therapeutics' stock price forecast for 2022?

2 analysts have issued 1 year price targets for Heron Therapeutics' stock. Their HRTX share price forecasts range from $5.50 to $12.00. On average, they predict the company's share price to reach $8.75 in the next year. This suggests a possible upside of 95.7% from the stock's current price.
View analysts price targets for HRTX
or view top-rated stocks among Wall Street analysts.

How have HRTX shares performed in 2022?

Heron Therapeutics' stock was trading at $9.13 at the start of the year. Since then, HRTX shares have decreased by 51.0% and is now trading at $4.47.
View the best growth stocks for 2022 here
.

When is Heron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our HRTX earnings forecast
.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) issued its earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.05. The biotechnology company earned $27.63 million during the quarter, compared to the consensus estimate of $24.65 million. Heron Therapeutics had a negative net margin of 239.34% and a negative trailing twelve-month return on equity of 457.73%. The business's quarterly revenue was up 23.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.62) EPS.

What guidance has Heron Therapeutics issued on next quarter's earnings?

Heron Therapeutics issued an update on its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $93.00 million-$95.00 million, compared to the consensus revenue estimate of $106.69 million.

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

How do I buy shares of Heron Therapeutics?

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $4.47.

How much money does Heron Therapeutics make?

Heron Therapeutics (NASDAQ:HRTX) has a market capitalization of $458.77 million and generates $86.35 million in revenue each year. The biotechnology company earns $-220,680,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

How many employees does Heron Therapeutics have?

The company employs 302 workers across the globe.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.herontx.com. The biotechnology company can be reached via phone at (858) 251-4400, via email at ir@herontx.com, or via fax at 650-365-6490.

This page (NASDAQ:HRTX) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.